This clinical trial is focused on studying Progressive Pulmonary Fibrosis (PPF), a lung disease where the tissue in the lungs becomes thick and stiff, making it difficult to breathe. The study will use a special imaging technique called PET/CT with a substance known as [18F]-AlF-FAPI-74. This substance is injected into the body and helps to highlight areas of the lungs that are affected by fibrosis or inflammation, which are two different types of tissue changes that can occur in PPF.
The purpose of the study is to see if this imaging method can help doctors tell the difference between areas of the lung that are mostly fibrotic (thickened tissue) and those that are mostly inflamed (swollen tissue). This could help in understanding the disease better and in deciding the best treatment approach for patients with PPF. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.
Participants in the study will undergo the PET/CT imaging process, which involves lying still while a machine takes detailed pictures of the inside of the body. The study will track how the [18F]-AlF-FAPI-74 substance behaves in the body and how it highlights the different types of lung tissue. The study aims to gather information over a period of time to see how well this imaging technique works in identifying the different patterns of lung changes in PPF.
The Netherlands 
